[Intermittent 2-phase therapy using ethambutol-INH-streptomycin].
D000293:Adolescent; D000328:Adult; D000995:Antitubercular Agents / Q000009:adverse effects; D004357:Drug Synergism; D004977:Ethambutol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007538:Isoniazid / Q000008:administration & dosage*; D008134:Long-Term Care; D008297:Male; D008875:Middle Aged; D009169:Mycobacterium tuberculosis / Q000302:isolation & purification; D009902:Optic Neuritis / Q000139:chemically induced; D010507:Periodicity; D013183:Sputum / Q000382:microbiology; D013307:Streptomycin / Q000008:administration & dosage*; D013997:Time Factors; D014397:Tuberculosis, Pulmonary / Q000188:drug therapy*
D000995:Antitubercular Agents; D004977:Ethambutol; D007538:Isoniazid; D013307:Streptomycin
Intermittierende 2-Phasentherapie mit Ethambutol-INH-Streptomycin.